[肥厚性心肌病治疗的发展前景:更新的AHA/ACC/多协会指南综述]。

IF 0.7 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS
Edoardo Bertero, Marco Canepa, Maurizio Pieroni, Iacopo Olivotto
{"title":"[肥厚性心肌病治疗的发展前景:更新的AHA/ACC/多协会指南综述]。","authors":"Edoardo Bertero, Marco Canepa, Maurizio Pieroni, Iacopo Olivotto","doi":"10.1714/4454.44487","DOIUrl":null,"url":null,"abstract":"<p><p>Therapeutic options for the treatment of hypertrophic obstructive cardiomyopathy have recently expanded with the introduction of myosin inhibitors, mavacamten and aficamten, which demonstrated a remarkable effect on functional capacity and symptoms of patients with left ventricular outflow tract obstruction. In recent years, there has also been a change in the approach to physical exercise in patients with hypertrophic cardiomyopathy, which now also includes the possibility of participating in high-intensity and competitive sports for selected patients with a low-risk profile. In this review, we explore the main innovations of the American College of Cardiology/American Heart Association guidelines on hypertrophic cardiomyopathy, we highlight the differences with the guidelines on the management of cardiomyopathies of the European Society of Cardiology, and we highlight some important unresolved issues in the management of the disease.</p>","PeriodicalId":12510,"journal":{"name":"Giornale italiano di cardiologia","volume":"26 3","pages":"185-194"},"PeriodicalIF":0.7000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[The evolving landscape of hypertrophic cardiomyopathy management: a review of the updated AHA/ACC/multisociety guidelines].\",\"authors\":\"Edoardo Bertero, Marco Canepa, Maurizio Pieroni, Iacopo Olivotto\",\"doi\":\"10.1714/4454.44487\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Therapeutic options for the treatment of hypertrophic obstructive cardiomyopathy have recently expanded with the introduction of myosin inhibitors, mavacamten and aficamten, which demonstrated a remarkable effect on functional capacity and symptoms of patients with left ventricular outflow tract obstruction. In recent years, there has also been a change in the approach to physical exercise in patients with hypertrophic cardiomyopathy, which now also includes the possibility of participating in high-intensity and competitive sports for selected patients with a low-risk profile. In this review, we explore the main innovations of the American College of Cardiology/American Heart Association guidelines on hypertrophic cardiomyopathy, we highlight the differences with the guidelines on the management of cardiomyopathies of the European Society of Cardiology, and we highlight some important unresolved issues in the management of the disease.</p>\",\"PeriodicalId\":12510,\"journal\":{\"name\":\"Giornale italiano di cardiologia\",\"volume\":\"26 3\",\"pages\":\"185-194\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Giornale italiano di cardiologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1714/4454.44487\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Giornale italiano di cardiologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1714/4454.44487","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

最近,随着肌球蛋白抑制剂马伐卡坦和阿非卡坦的引入,肥厚性梗阻性心肌病的治疗选择得到了扩展,这两种药物对左心室流出道梗阻患者的功能容量和症状有显著影响。近年来,肥厚性心肌病患者的体育锻炼方法也发生了变化,现在还包括选择低风险患者参加高强度和竞争性运动的可能性。在这篇综述中,我们探讨了美国心脏病学会/美国心脏协会关于肥厚性心肌病指南的主要创新,我们强调了与欧洲心脏病学会关于肥厚性心肌病管理指南的差异,我们强调了在疾病管理中一些重要的未解决的问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[The evolving landscape of hypertrophic cardiomyopathy management: a review of the updated AHA/ACC/multisociety guidelines].

Therapeutic options for the treatment of hypertrophic obstructive cardiomyopathy have recently expanded with the introduction of myosin inhibitors, mavacamten and aficamten, which demonstrated a remarkable effect on functional capacity and symptoms of patients with left ventricular outflow tract obstruction. In recent years, there has also been a change in the approach to physical exercise in patients with hypertrophic cardiomyopathy, which now also includes the possibility of participating in high-intensity and competitive sports for selected patients with a low-risk profile. In this review, we explore the main innovations of the American College of Cardiology/American Heart Association guidelines on hypertrophic cardiomyopathy, we highlight the differences with the guidelines on the management of cardiomyopathies of the European Society of Cardiology, and we highlight some important unresolved issues in the management of the disease.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Giornale italiano di cardiologia
Giornale italiano di cardiologia CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
1.10
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信